Avanos Medical, Inc. (NYSE:AVNS) Q2 2024 Earnings Conference Call July 31, 2024 9:00 AM ET

Company Participants

Scott Galovan - SVP, Strategy & Corporate Development
Joe Woody - Chief Executive Officer
Michael Greiner - SVP, Chief Financial Officer & Chief Transformation Officer

Conference Call Participants

Kristen Stewart - CL King
Rick Wise - Stifel
Daniel Stauder - Citizens JMP

Operator

Good morning, ladies and gentlemen, and welcome to the Avanos Medical Q2 2024 Earnings Call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. [Operator Instructions] This call is being recorded on Wednesday, July 31, 2024.

I would now like to turn the conference over to Scott Galovan, Senior Vice President, Strategy and Corporate Development. Please go ahead.

Scott Galovan

Good morning, everyone, and thanks for joining us. It's my pleasure to welcome you to Avanos 2024 second quarter earnings conference call.

Presenting today will be Joe Woody, CEO; and Michael Greiner, Senior Vice President, CFO, and Chief Transformation Officer. Joe will review our second quarter results and current business environment, as well as provide an update on our transformation efforts. Michael will share additional details regarding these topics and affirm our 2024 planning assumptions. We will finish the call with Q&A. A presentation for today's call is available on the Investors section of our website avanos.com.

As a reminder, our comments today contain forward-looking statements related to the company, our expected performance, current economic conditions and our industry. No assurance can be given as to future financial results. Actual results could differ materially from those in the forward-looking statements. For more information about forward-looking statements and the risk factors that could influence future results, please see today's press release and risk factors described in our filings with the SEC.

Additionally, we'll be referring to adjusted results and outlook. The press release has information on these adjustments and reconciliations to comparable GAAP financial measures.

Now, I'll turn the call over to Joe.

Joe Woody

Thanks, Scott. Good morning, everyone, and thank you for joining us to review our operational and financial results for the second quarter 2024.

Building off our first quarter results, we delivered a strong second quarter as Digestive Health continued its solid performance, and we experienced additional positive shifts in our Pain Management and Recovery business. As we noted in our prior earnings calls this year, our quarterly performance for 2024 will improve as the year progresses.